Amarin Corp Plc (AMRN)

[ziploc_1]

NSl...QUOTE from the Glaxo-Teva infringement case..."Post-MI LVD “is intertwined with heart failure.”...This is IMO the key to the Glaxo vs. Teva case

Even Teva’s expert acknowledged during the case that..."some post-MI LVD patients have CHF."

Also Hickma announced at an analyst meeting that they were predicting selling over a million Rx's for their gV product...despite the fact that the over 500 trigs/dcl indication for gV is 'intertwined with CVD' and is a vanishingly small share of the market(less than 10% as opposed to the CVD indication being over 90% of the market).

These facts lead to the inevitable conclusion that Hickma intended to infringe on Amarin's valid patent for the CVD indication as it has already done.